Supply of products by Sanofi-Aventis Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and standards of therapeutic goods in Australia, addressing issues related to safety, efficacy, and quality of products such as medicines, medical devices, and blood products. The Act is overseen by the Australian Parliament and aims to protect public health by ensuring that therapeutic goods meet acceptable standards before they are made available in the market. On 13 February 2013, a notice was issued under sections 14 and 14A of the Act by the delegate of the Secretary of the Department of Health and Ageing, permitting Sanofi-Aventis Australia Pty Ltd to supply certain products that did not fully comply with the labelling requirements specified in Therapeutic Goods Order 69. This consent allowed the supply of irbesartan and irbesartan and hydrochlorothiazide tablets, which had the previous sponsor's details on the labels instead of the new sponsor's. The consent was granted under specific conditions, including the maintenance of the existing label design, no other changes to the products, and the establishment of a mechanism for addressing any inquiries or complaints about the products.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and individuals involved in the supply and distribution of therapeutic goods within Australia. This includes pharmaceutical companies, healthcare providers, and other businesses engaged in the manufacture, supply, or advertising of therapeutic goods. The Act is enforced at the Commonwealth level and applies across the entirety of Australia. However, specific conditions and consents, such as the one described in the notice issued on February 13, 2013, may apply to particular products or companies. The Act allows for the extension or restriction of its application through subordinate instruments such as regulations and orders, which can provide additional detail on compliance and enforcement. In this instance, the consent granted to Sanofi-Aventis Australia Pty Ltd involves the supply of specific products that do not conform to certain labelling requirements but are otherwise subject to stringent conditions, ensuring that the products are managed and labelled appropriately for consumer safety and regulatory compliance.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") encompasses a range of provisions governing the regulation of therapeutic goods in Australia. Specifically, section 14 and section 14A of the Act pertain to the supply of therapeutic goods that do not conform to certain standards. In this context, the delegate of the Secretary of the Department of Health and Ageing has granted consent under these sections for Sanofi-Aventis Australia Pty Ltd to supply certain products. These products include various dosages of irbesartan and irbesartan combined with hydrochlorothiazide, which are currently not compliant with the requirements of paragraph 3(l) of Therapeutic Goods Order 69 due to the presence of the previous sponsor's details on the labels. The obligations under this consent are quite specific. Firstly, the supply of the non-compliant products is permitted only until February 13, 2014. Secondly, the labels for these products must remain identical to those previously approved for Bristol-Myers Squibb Australia Pty Ltd, including the logo and address details. Thirdly, no other changes are allowed to the listed products. Additionally, the Company must ensure that any inquiries or complaints about these products are promptly referred to them. Failure to comply with the conditions set out in the consent could lead to various legal consequences. While the specific legal text does not enumerate explicit offences or penalties within this notice, the Act generally provides for enforcement actions under sections that deal with contraventions of legislative requirements. Such actions could include fines or other penalties as stipulated by the Therapeutic Goods Act 1989 or related regulations. Additionally, non-compliance might result in product recalls, further regulatory scrutiny, or even criminal charges depending on the severity and intent behind the breach. The maximum penalties for such offences can vary, but they often include substantial fines and potential imprisonment for serious or repeated violations.